|
|
Vaccine Detail
|
Neoantigen DNA Vaccine |
| Vaccine Information |
- Vaccine Name: Neoantigen DNA Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: neoantigen (NCT03598816)
- Immunization Route: Intramuscular injection (i.m.)
- Description: Personalized neoantigen DNA vaccine may enhance anti-tumor immune response in Renal Cell Carcinoma in combination with checkpoint inhibitors ipilimumab (anti-CTLA-4 antibody) and nivolumab (anti-PD-1 antibody). (NCT03598816)
|
| Host Response |
|
|
| References |
NCT03598816: PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/​Metastatic Renal Cell Carcinoma (PIVOT-RCC) [https://clinicaltrials.gov/study/NCT03598816]
|
|
